Person · CIK 1293171

Gilbert H Kliman

Director at GLAUKOS

Earlier: Staar Surgical, Doximity, Braze, PMV Pharmaceuticals, Avedro, Venus Concept, Obalon Therapeutics, Eiger BioPharmaceuticals, Invuity, Carbylan Therapeutics, Marketo, Applied Genetic Technologies, Macrogenics, TESARO, Transcept Pharmaceuticals, Epocrates, Trius Therapeutics, Metabasis Therapeutics, Anesiva, EnteroMedics, Intralase and Myogen

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$305.3M

Noticed on Form 144$7M

Bought on Form 4$41.4M

Companies23

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
GLAUKOS GKOS	Common Stock	Directly	37,406	Nov 4, 2026 · Filing · EDGAR
GLAUKOS GKOS	Common Stock	Through InterWest Partners IX, L.P.	1,018,362	May 31, 2018 · Filing · EDGAR
GLAUKOS GKOS	Common Stock	By InterWest Partners X, LP	333,917	May 18, 2022 · Filing · EDGAR
GLAUKOS GKOS	Common Stock	By InterWest Venture Management Co.	13,965	May 18, 2022 · Filing · EDGAR
GLAUKOS GKOS	Common Stock	See footnote below	7,995	Jun 7, 2019 · Filing · EDGAR
GLAUKOS GKOS	Stock Option (Right to Buy) exercise $25.77, expires Dec 13, 2027, into Common Stock	Directly	10,000	Nov 4, 2026 · Filing · EDGAR
Staar Surgical	Common Stock	Directly	10,457	Dec 1, 2023 · Filing · EDGAR
Staar Surgical	Common Stock Options exercise $154.96, expires Jun 23, 2031, into Common Stock	Directly	850	Jun 24, 2021 · Filing · EDGAR
Doximity	Class A Common Stock	Directly	449,960	Aug 2, 2022 · Filing · EDGAR
Doximity	Class B Common Stock into Class A Common Stock	By InterWest Partners X, L.P.	8,556,998	Dec 2, 2021 · Filing · EDGAR
Braze	Class A Common Stock	By: InterWest Partners X, LP	3,394,219	Feb 8, 2022 · Filing · EDGAR
PMV Pharmaceuticals	Common Stock	Directly	4,469,911	Jul 13, 2021 · Filing · EDGAR
PMV Pharmaceuticals	Commonn Stock	Directly	55,000	Sep 25, 2020 · Filing · EDGAR
PMV Pharmaceuticals	Common Stock	By Gilbert H. Kliman	25,552	Jul 13, 2021 · Filing · EDGAR
PMV Pharmaceuticals	Common Stock	By: Khaled A. Nasr	4,201	Jul 13, 2021 · Filing · EDGAR
PMV Pharmaceuticals	Common Stock	By: Keval Desai	2,816	Jul 13, 2021 · Filing · EDGAR
Avedro	Restricted Stock Units into Common Stock	Directly	3,005	Jun 14, 2019 · Filing · EDGAR
Venus Concept	Common Stock	See footnote	658,657	Nov 7, 2019 · Filing · EDGAR
Obalon Therapeutics	Common Stock	Directly	380,224	Aug 6, 2019 · Filing · EDGAR
Eiger BioPharmaceuticals	Common Stock	Directly	1,362,327	Oct 18, 2018 · Filing · EDGAR
Invuity	Common Stock	Directly	1,080,272	Jun 18, 2015 · Filing · EDGAR
Carbylan Therapeutics	Common Stock	See Footnote	4,619,196	Apr 14, 2015 · Filing · EDGAR
Marketo	Common Stock	Directly	3,715,756	May 28, 2014 · Filing · EDGAR
Marketo	Common Stock	See footnote	7,663,756	Sep 18, 2013 · Filing · EDGAR
Marketo	Common Stock	By Arnold L. Oronsky	120,819	May 28, 2014 · Filing · EDGAR
Marketo	Common Stock	By Philip T. Gianos	49,266	May 30, 2014 · Filing · EDGAR
Marketo	Common Stock	By W. Stephen Holmes	30,204	May 28, 2014 · Filing · EDGAR
Applied Genetic Technologies	Common Stock	See Footnote	1,452,216	Apr 1, 2014 · Filing · EDGAR
Macrogenics	Common Stock	See Footnote	1,908,716	Oct 16, 2013 · Filing · EDGAR
TESARO	Common Stock	Directly	2,471,701	Aug 5, 2013 · Filing · EDGAR
Transcept Pharmaceuticals	Common	Directly	1,983,884	Sep 21, 2011 · Filing · EDGAR
Epocrates	Common Stock	See Footnote	87,087	Feb 7, 2011 · Filing · EDGAR
Trius Therapeutics	Common Stock	Directly	3,548,643	Aug 6, 2010 · Filing · EDGAR
Metabasis Therapeutics	Common	Directly	3,717,282	Apr 16, 2008 · Filing · EDGAR
Metabasis Therapeutics	Common	By InterWest Investors VII, L.P.	177,970	Apr 16, 2008 · Filing · EDGAR
Metabasis Therapeutics	Common Stock	By: InterWest Investors VII, LP	120,220	Sep 30, 2005 · Filing · EDGAR
Metabasis Therapeutics	Common	See Footnote 3	50,000	Apr 16, 2008 · Filing · EDGAR
Metabasis Therapeutics	Common Stock	See footnote	5,941	Jun 21, 2004 · Filing · EDGAR
Anesiva	Common	Directly	4,627,266	Dec 18, 2007 · Filing · EDGAR
Anesiva	Common Stock	by InterWest Partners VIII, LP	2,721,685	Mar 17, 2006 · Filing · EDGAR
Anesiva	Common	By InterWest Investors Q VIII, L.P.	132,388	Dec 18, 2007 · Filing · EDGAR
Anesiva	Common Stock	by InterWest Investors Q VIII, LP	77,870	Mar 17, 2006 · Filing · EDGAR
Anesiva	Common	By InterWest Investors VIII, L.P.	37,079	Dec 18, 2007 · Filing · EDGAR
Anesiva	Common Stock	by InterWest Investors VIII, LP	21,869	Mar 17, 2006 · Filing · EDGAR
Anesiva	Common	By Gilbert H. Kliman	12,282	Dec 18, 2007 · Filing · EDGAR
Anesiva	Common Stock	By Kliman Trust dated 11/15/02	6,283	Dec 15, 2005 · Filing · EDGAR
Anesiva	Common	By Christopher B. Ehrlich	2,237	Dec 18, 2007 · Filing · EDGAR
Anesiva	Common	By Philip T. Gianos	320	Dec 18, 2007 · Filing · EDGAR
Anesiva	Common Stock	By Thomas L. Rosch	298	Dec 15, 2005 · Filing · EDGAR
Anesiva	Common	By Harvey B. Cash	278	Dec 18, 2007 · Filing · EDGAR
Anesiva	Common	By H. Ronald Nash	159	Dec 18, 2007 · Filing · EDGAR
Anesiva	Common	By W. Scott Hedrick	96	Dec 18, 2007 · Filing · EDGAR
Anesiva	Common	By W. Stephen Holmes	78	Dec 18, 2007 · Filing · EDGAR
Anesiva	Common Stock	see footnote	64	Dec 15, 2005 · Filing · EDGAR
EnteroMedics	Common Stock	Directly	1,546,761	Nov 20, 2007 · Filing · EDGAR
Intralase	Common Stock	By Ltd. Partnership	3,387,376	Apr 1, 2005 · Filing · EDGAR
Intralase	Common Stock	By InterWest Partners VIII, L.P.	604,944	Oct 13, 2004 · Filing · EDGAR
Intralase	Common Stock	By InterWest Investors Q VIII, L.P.	17,317	Oct 13, 2004 · Filing · EDGAR
Intralase	Common Stock	By InterWest Investors VIII, L.P.	5,155	Oct 13, 2004 · Filing · EDGAR
Myogen	Common Stock	Directly	835,969	Jun 28, 2005 · Filing · EDGAR
Myogen	Common Stock	by Gilbert H. Kliman	10,771	Jun 28, 2005 · Filing · EDGAR
Myogen	Common Stock	by InterWest Management Parnters VI, LLC	2,787	Jun 28, 2005 · Filing · EDGAR
Myogen	Common Stock	by Philip T. Gianos	1,327	Jun 28, 2005 · Filing · EDGAR
Myogen	Common Stock	by Harvey B. Cash	758	Jun 28, 2005 · Filing · EDGAR
Myogen	Common Stock	by Robert R. Momsen	398	Jun 28, 2005 · Filing · EDGAR
Myogen	Common Stock	by W. Scott Hedrick	330	Jun 28, 2005 · Filing · EDGAR
Myogen	Common Stock	by W. Stephen Holmes	291	Jun 28, 2005 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q4 2026	$633K	$633K	—
Q3 2026	$475K	$475K	—
Q2 2026	$1.4M	$1.4M	—
Q4 2025	$536K	$536K	—
Q4 2024	$1.8M	$1.8M	—
Q3 2024	$392K	$392K	—
Q2 2024	$560K	$560K	—
Q1 2024	$1.9M	$441K	—
Q3 2023	$746K	$746K	—
Q3 2022	$178K	Not machine-readable	—
Q1 2022	$1.7M	Not machine-readable	—
Q4 2021	$70.5M	Not machine-readable	—
Q2 2021	$105.4M	Not machine-readable	—
Q3 2020	—	—	$2M
Q3 2019	—	—	$100K
Q1 2019	—	—	$350K
Q4 2018	$2.9M	Not machine-readable	—
Q3 2018	$30.4M	Not machine-readable	$5M
Q2 2015	—	—	$4.1M
Q2 2014	$4.4M	Not machine-readable	$905K
Q1 2014	$2.5M	Not machine-readable	—
Q3 2013	$70.8M	Not machine-readable	—
Q3 2012	—	—	$6M
Q3 2011	—	—	$1.6M
Q1 2011	$6.8M	Not machine-readable	—
Q3 2010	—	—	$6.1M
Q2 2008	—	—	$2.3M
Q4 2007	—	—	$9.5M
Q2 2006	$1.3M	Not machine-readable	—
Q1 2006	—	—	$55K
Q3 2005	—	—	$2.5M
Q2 2005	$46K	Not machine-readable	—
Q2 2004	—	—	$910K

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
GLAUKOS GKOS · Fidelity Brokerage Services · No 10b5-1 plan stated · 10 notices
Nov 4, 2026	2,500 · ~$633K	Nov 4, 2026	Sold as noticed Sold 2,500 at $253.00 on Nov 4 · $633K Form 4	Filing · EDGAR
Aug 19, 2026	2,500 · ~$475K	Aug 19, 2026	Sold as noticed Sold 2,500 at $190.00 on Aug 19 · $475K Form 4	Filing · EDGAR
May 14, 2026	5,000 · ~$704K	May 14, 2026	Sold as noticed Sold 5,000 at $140.76 on May 14 · $704K Form 4	Filing · EDGAR
May 11, 2026	5,000 · ~$675K	May 11, 2026	Sold as noticed Sold 5,000 at $135.00 on May 11 · $675K Form 4	Filing · EDGAR
Dec 9, 2025	5,000 · ~$536K	Dec 9, 2025	Sold as noticed Sold 5,000 at $107.27 on Dec 9 · $536K Form 4	Filing · EDGAR
Dec 11, 2024	2,000 · ~$288K	Dec 11, 2024	Sold as noticed Sold 2,000 at $144.01 on Dec 11 · $288K Form 4	Filing · EDGAR
Sep 9, 2024	3,000 · ~$392K	Sep 9, 2024	Sold as noticed Sold 3,000 in 2 sales, Sep 9 to Sep 9 · $392K Form 4	Filing · EDGAR
May 30, 2024	5,000 · ~$560K	May 30, 2024	Sold as noticed Sold 5,000 at $112.00 on May 30 · $560K Form 4	Filing · EDGAR
Mar 7, 2024	5,000 · ~$441K	Mar 7, 2024	Partly sold Sold 3,145 at $86.01 on Mar 6 · $271K likely match Form 4	Filing · EDGAR
Aug 4, 2023	10,000 · ~$746K	Aug 4, 2023	Sold as noticed Sold 10,000 at $74.56 on Aug 4 · $746K Form 4	Filing · EDGAR
GLAUKOS GKOS · Fidelity Brokerage Services · 10b5-1 plan adopted Jun 15, 2024 · 1 notice
Dec 20, 2024	10,000 · ~$1.5M	Dec 20, 2024	Sold as noticed Sold 10,000 at $150.28 on Dec 20 · $1.5M Form 4	Filing · EDGAR
Sales without a matching Form 144 · 41 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Sold without notice GLAUKOS (GKOS): Sold 5,000 at $88.25 on Mar 7, 2024 · $441K	Filing · EDGAR
—	—	—	Sold without notice GLAUKOS (GKOS): Sold 5,202 at $84.93 on Mar 6, 2024 · $442K	Filing · EDGAR
—	—	—	Sold without notice GLAUKOS (GKOS): Sold 8,000 at $92.00 on Feb 27, 2024 · $736K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS (GKOS): Sold 3,362 at $53.01 on Aug 5, 2022 · $178K	Filing · EDGAR
—	—	—	Notice not machine-readable Doximity: Sold 826 at $59.00 on Feb 25, 2022 · $49K	Filing · EDGAR
—	—	—	Notice not machine-readable Doximity: Sold 29,174 at $56.09 on Feb 23, 2022 · $1.6M	Filing · EDGAR
—	—	—	Notice not machine-readable Doximity: Sold 5,980 at $62.00 on Dec 7, 2021 · $371K	Filing · EDGAR
—	—	—	Notice not machine-readable Doximity: Sold 8,912 at $63.00 on Dec 7, 2021 · $561K	Filing · EDGAR
—	—	—	Notice not machine-readable Doximity: Sold 2,000 at $65.82 on Dec 3, 2021 · $132K	Filing · EDGAR
—	—	—	Notice not machine-readable Braze: Sold 1,130,000 at $61.42 on Nov 19, 2021 · $69.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Doximity: Sold 4,289,250 at $24.57 on Jun 28, 2021 · $105.4M	Filing · EDGAR
—	—	—	Notice not machine-readable Eiger BioPharmaceuticals: Sold 26,465 at $12.00 on Oct 18, 2018 · $318K	Filing · EDGAR
—	—	—	Notice not machine-readable Eiger BioPharmaceuticals: Sold 210,800 at $12.07 on Oct 18, 2018 · $2.5M	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS (GKOS): Sold 2,760 at $62.39 on Aug 30, 2018 · $172K	Filing · EDGAR
—	—	—	Notice not machine-readable GLAUKOS (GKOS): Sold 500,000 at $60.38 on Aug 29, 2018 · $30.2M	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 16,613 at $23.06 on May 30, 2014 · $383K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 1,034 at $24.16 on May 30, 2014 · $25K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 19,373 at $23.20 on May 30, 2014 · $449K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 22,090 at $24.57 on May 29, 2014 · $543K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 23,133 at $24.57 on May 29, 2014 · $568K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 9,118 at $24.56 on May 29, 2014 · $224K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 11,298 at $24.59 on May 29, 2014 · $278K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 21,821 at $24.58 on May 29, 2014 · $536K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 5,000 at $24.00 on May 21, 2014 · $120K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 5,000 at $24.02 on May 20, 2014 · $120K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 15,000 at $22.96 on May 16, 2014 · $344K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 8,463 at $24.34 on May 14, 2014 · $206K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 14,695 at $24.26 on May 13, 2014 · $356K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 11,298 at $24.25 on May 13, 2014 · $274K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 5,000 at $41.56 on Feb 28, 2014 · $208K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 19,420 at $42.06 on Feb 27, 2014 · $817K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 13,050 at $40.03 on Feb 26, 2014 · $522K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 20,000 at $40.62 on Feb 26, 2014 · $812K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 4,350 at $40.70 on Feb 13, 2014 · $177K	Filing · EDGAR
—	—	—	Notice not machine-readable Marketo: Sold 2,083,435 at $33.99 on Sep 18, 2013 · $70.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Epocrates: Sold 18,822 at $16.00 on Feb 7, 2011 · $301K	Filing · EDGAR
—	—	—	Notice not machine-readable Epocrates: Sold 407,401 at $16.00 on Feb 7, 2011 · $6.5M	Filing · EDGAR
—	—	—	Notice not machine-readable Intralase: Sold 2,054 at $19.50 on May 19, 2006 · $40K	Filing · EDGAR
—	—	—	Notice not machine-readable Intralase: Sold 13,927 at $20.47 on May 1, 2006 · $285K	Filing · EDGAR
—	—	—	Notice not machine-readable Intralase: Sold 46,746 at $20.47 on May 1, 2006 · $957K	Filing · EDGAR
—	—	—	Notice not machine-readable Intralase: Sold 2,408 at $19.22 on Jun 16, 2005 · $46K	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

GLAUKOS GKOS Director · filings 2015 to 2026 · sold $38.9M · $7M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 4, 2026	Option or RSU exercised or converted	+2,500	$25.77	$64K	39,906 direct	Filing · EDGAR
Nov 4, 2026	Open-market or private sale	−2,500	$253.00	$633K	37,406 direct	Filing · EDGAR
Nov 4, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−2,500			10,000 direct	Filing · EDGAR
Aug 19, 2026	Option or RSU exercised or converted	+2,500	$25.77	$64K	39,906 direct	Filing · EDGAR
Aug 19, 2026	Open-market or private sale	−2,500	$190.00	$475K	37,406 direct	Filing · EDGAR
Aug 19, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−2,500			12,500 direct	Filing · EDGAR
May 28, 2026	Grant or award from the company Stock Option (Right to Buy)	+2,987			2,987 direct	Filing · EDGAR
May 28, 2026	Grant or award from the company	+1,878			37,406 direct	Filing · EDGAR
May 14, 2026	Option or RSU exercised or converted	+5,000	$24.69	$123K	40,528 direct	Filing · EDGAR
May 14, 2026	Open-market or private sale	−5,000	$140.76	$704K	35,528 direct	Filing · EDGAR
May 14, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000	$24.69	$123K	0 direct	Filing · EDGAR
May 11, 2026	Option or RSU exercised or converted	+5,000	$24.69	$123K	40,528 direct	Filing · EDGAR
May 11, 2026	Open-market or private sale	−5,000	$135.00	$675K	35,528 direct	Filing · EDGAR
May 11, 2026	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000	$24.69	$123K	5,000 direct	Filing · EDGAR
Jan 2, 2026	Grant or award from the company	+623			35,528 direct	Filing · EDGAR
Dec 9, 2025	Option or RSU exercised or converted	+5,000	$24.69	$123K	39,905 direct	Filing · EDGAR
Dec 9, 2025	Open-market or private sale	−5,000	$107.27	$536K	34,905 direct	Filing · EDGAR
Dec 9, 2025	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000	$24.69	$123K	10,000 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company	+2,108			34,905 direct	Filing · EDGAR
May 29, 2025	Grant or award from the company Stock Option (Right to Buy)	+3,149			3,149 direct	Filing · EDGAR
Jan 2, 2025	Grant or award from the company	+461			32,797 direct	Filing · EDGAR
Dec 20, 2024	Option or RSU exercised or converted	+10,000	$32.00	$320K	42,336 direct	Filing · EDGAR
Dec 20, 2024	Sale under a 10b5-1 plan	−10,000	$150.28	$1.5M	32,336 direct	Filing · EDGAR
Dec 20, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			0 direct	Filing · EDGAR
Dec 11, 2024	Option or RSU exercised or converted	+2,000	$32.00	$64K	34,336 direct	Filing · EDGAR
Dec 11, 2024	Open-market or private sale	−2,000	$144.01	$288K	32,336 direct	Filing · EDGAR
Dec 11, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−2,000			10,000 direct	Filing · EDGAR
Sep 9, 2024	Option or RSU exercised or converted	+3,000	$32.00	$96K	35,336 direct	Filing · EDGAR
Sep 9, 2024	Open-market or private sale	−2,000	$131.00	$262K	33,336 direct	Filing · EDGAR
Sep 9, 2024	Open-market or private sale	−1,000	$130.00	$130K	32,336 direct	Filing · EDGAR
Sep 9, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−3,000			12,000 direct	Filing · EDGAR
May 30, 2024	Option or RSU exercised or converted	+5,000	$32.00	$160K	35,620 direct	Filing · EDGAR
May 30, 2024	Open-market or private sale	−5,000	$112.00	$560K	30,620 direct	Filing · EDGAR
May 30, 2024	Grant or award from the company	+1,716			32,336 direct	Filing · EDGAR
May 30, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			15,000 direct	Filing · EDGAR
May 30, 2024	Grant or award from the company Stock Option (Right to Buy)	+1,246			1,246 direct	Filing · EDGAR
Mar 7, 2024	Option or RSU exercised or converted	+5,000	$32.00	$160K	35,620 direct	Filing · EDGAR
Mar 7, 2024	Open-market or private sale	−5,000	$88.25	$441K	30,620 direct	Filing · EDGAR
Mar 7, 2024	Option or RSU exercised or converted Stock Option (Right to Buy)	−5,000			20,000 direct	Filing · EDGAR
Mar 6, 2024	Open-market or private sale	−3,145	$86.01	$271K	5,202 By InterWest Venture Management Company	Filing · EDGAR
Mar 6, 2024	Open-market or private sale	−5,202	$84.93	$442K	0 By InterWest Venture Management Company	Filing · EDGAR
Feb 27, 2024	Open-market or private sale	−8,000	$92.00	$736K	8,347 By InterWest Venture Management Company	Filing · EDGAR
Jan 2, 2024	Grant or award from the company	+895			30,620 direct	Filing · EDGAR
Aug 4, 2023	Option or RSU exercised or converted	+10,000	$7.28	$73K	39,725 direct	Filing · EDGAR
Aug 4, 2023	Open-market or private sale	−10,000	$74.56	$746K	29,725 direct	Filing · EDGAR
Aug 4, 2023	Option or RSU exercised or converted Stock Option (Right to Buy)	−10,000			0 direct	Filing · EDGAR
Jun 1, 2023	Grant or award from the company	+3,230			29,725 direct	Filing · EDGAR
Jan 3, 2023	Grant or award from the company	+1,572			26,495 direct	Filing · EDGAR
Aug 19, 2022	Other acquisition or disposition (see the filing)	−2,382			24,923 direct	Filing · EDGAR
Aug 19, 2022	Other acquisition or disposition (see the filing)	+2,382			16,347 By InterWest Venture Management Company	Filing · EDGAR
Aug 5, 2022	Open-market or private sale	−3,362	$53.01	$178K	0 By InterWest Partners IX, LP	Filing · EDGAR
Aug 4, 2022	Other acquisition or disposition (see the filing)	−333,917			0 InterWest Partners X, LP	Filing · EDGAR
Aug 4, 2022	Other acquisition or disposition (see the filing)	+83,955			83,955 InterWest Management Partners X, LLC	Filing · EDGAR
Aug 4, 2022	Other acquisition or disposition (see the filing)	−83,955			0 InterWest Management Partners X, LLC	Filing · EDGAR
Aug 4, 2022	Other acquisition or disposition (see the filing)	+19,045			27,305 direct	Filing · EDGAR
Jun 2, 2022	Grant or award from the company	+4,364			8,260 direct	Filing · EDGAR
May 18, 2022	Other acquisition or disposition (see the filing)	−980			3,896 direct	Filing · EDGAR
May 18, 2022	Other acquisition or disposition (see the filing)	+980			13,965 By InterWest Venture Management Co.	Filing · EDGAR
Sep 8, 2021	Other acquisition or disposition (see the filing)	−3,900			4,876 direct	Filing · EDGAR
Sep 8, 2021	Other acquisition or disposition (see the filing)	+3,900			12,985 By InterWest Venture Management Company	Filing · EDGAR

36 earlier transactions are in the filing list below.

Staar Surgical Director · filings 2020 to 2023

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 1, 2023	Grant or award from the company	+366	$32.99	$12K	10,457 direct	Filing · EDGAR
Sep 29, 2023	Grant or award from the company	+435	$40.18	$17K	10,091 direct	Filing · EDGAR
Jun 15, 2023	Option or RSU exercised or converted	+3,417			9,656 direct	Filing · EDGAR
Jun 16, 2022	Option or RSU exercised or converted	+355			3,340 direct	Filing · EDGAR
Jun 16, 2022	Option or RSU exercised or converted	+2,899			6,239 direct	Filing · EDGAR
Jun 24, 2021	Grant or award from the company	+404			2,985 direct	Filing · EDGAR
Jun 24, 2021	Option or RSU exercised or converted Common Stock Options	+850			850 direct	Filing · EDGAR
Jul 30, 2020	Grant or award from the company	+2,117			2,581 direct	Filing · EDGAR
Jun 1, 2020	Grant or award from the company	+464			464 direct	Filing · EDGAR

Doximity Other · filings 2021 to 2022 · sold $108.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 2, 2022	Returned to the company	−4,714			449,960 direct	Filing · EDGAR
Jul 27, 2022	Grant or award from the company	+4,714			454,674 direct	Filing · EDGAR
Feb 25, 2022	Open-market or private sale	−826	$59.00	$49K	449,960 direct	Filing · EDGAR
Feb 23, 2022	Open-market or private sale	−29,174	$56.09	$1.6M	450,786 direct	Filing · EDGAR
Dec 7, 2021	Open-market or private sale	−8,912	$63.00	$561K	485,940 direct	Filing · EDGAR
Dec 7, 2021	Open-market or private sale	−5,980	$62.00	$371K	479,960 direct	Filing · EDGAR
Dec 3, 2021	Open-market or private sale	−2,000	$65.82	$132K	494,852 direct	Filing · EDGAR
Dec 2, 2021	Derivative converted	+4,300,000	$0.00	$4K	4,300,000 By InterWest Partners X, L.P.	Filing · EDGAR
Dec 2, 2021	Other acquisition or disposition (see the filing)	−4,300,000			0 By InterWest Partners X, L.P.	Filing · EDGAR
Dec 2, 2021	Other acquisition or disposition (see the filing)	+1,101,094			1,101,094 By: InterWest Management Partners X, LLC	Filing · EDGAR
Dec 2, 2021	Other acquisition or disposition (see the filing)	−1,101,094			0 By: InterWest Management Partners X, LLC	Filing · EDGAR
Dec 2, 2021	Other acquisition or disposition (see the filing)	+249,778			496,852 direct	Filing · EDGAR
Dec 2, 2021	Derivative converted Class B Common Stock	−4,300,000			8,556,998 By InterWest Partners X, L.P.	Filing · EDGAR
Nov 12, 2021	Derivative converted	+4,300,000	$0.00	$4K	4,300,000 By InterWest Partners X, L.P.	Filing · EDGAR
Nov 12, 2021	Other acquisition or disposition (see the filing)	−4,300,000			0 By InterWest Partners X, L.P.	Filing · EDGAR
Nov 12, 2021	Other acquisition or disposition (see the filing)	+1,089,179			1,089,179 By: InterWest Management Partners X, LLC	Filing · EDGAR
Nov 12, 2021	Other acquisition or disposition (see the filing)	−1,089,179			0 By: InterWest Management Partners X, LLC	Filing · EDGAR
Nov 12, 2021	Other acquisition or disposition (see the filing)	+247,074			247,074 direct	Filing · EDGAR
Nov 12, 2021	Derivative converted Class B Common Stock	−4,300,000			12,856,998 By InterWest Partners X, L.P.	Filing · EDGAR
Jun 28, 2021	Derivative converted	+4,289,250	$0.00	$4K	4,289,250 By InterWest Partners X, L.P.	Filing · EDGAR
Jun 28, 2021	Open-market or private sale	−4,289,250	$24.57	$105.4M	0 By InterWest Partners X, L.P.	Filing · EDGAR
Jun 28, 2021	Derivative converted Series A Preferred Stock	−13,296,504			0 By InterWest Partners X, L.P.	Filing · EDGAR
Jun 28, 2021	Derivative converted Series B Preferred Stock	−5,412,972			0 By InterWest Partners X, L.P.	Filing · EDGAR
Jun 28, 2021	Derivative converted Series C Preferred Stock	−2,736,772			0 By InterWest Partners X, L.P.	Filing · EDGAR
Jun 28, 2021	Derivative converted Class B Common Stock	+21,446,248			21,446,248 By InterWest Partners X, L.P.	Filing · EDGAR
Jun 28, 2021	Derivative converted Class B Common Stock	−4,289,250			17,156,998 By InterWest Partners X, L.P.	Filing · EDGAR

Braze 10% owner · filings 2021 to 2022 · sold $69.4M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 8, 2022	Derivative converted	+3,394,219	$0.00	$3K	3,394,219 By: InterWest Partners X, LP	Filing · EDGAR
Feb 8, 2022	Derivative converted Class B Common Stock	−3,394,219			0 By: InterWest Partners X, LP	Filing · EDGAR
Nov 19, 2021	Derivative converted	+4,524,219			4,524,219 By InterWest Partners X, L.P.	Filing · EDGAR
Nov 19, 2021	Other acquisition or disposition (see the filing)	−4,524,219			0 By InterWest Partners X, L.P.	Filing · EDGAR
Nov 19, 2021	Derivative converted	+1,130,000			1,130,000 By InterWest Partners X, L.P.	Filing · EDGAR
Nov 19, 2021	Open-market or private sale	−1,130,000	$61.42	$69.4M	0 By InterWest Partners X, L.P.	Filing · EDGAR
Nov 19, 2021	Derivative converted Series B Preferred Stock	−2,824,395			0 By InterWest Partners X, L.P.	Filing · EDGAR
Nov 19, 2021	Derivative converted Series C Preferred Stock	−1,603,848			0 By InterWest Partners X, L.P.	Filing · EDGAR
Nov 19, 2021	Derivative converted Series D Preferred Stock	−95,976			0 By InterWest Partners X, L.P.	Filing · EDGAR
Nov 19, 2021	Other acquisition or disposition (see the filing) Class B Common Stock	+4,524,219			4,524,219 By InterWest Partners X, L.P.	Filing · EDGAR
Nov 19, 2021	Derivative converted Class B Common Stock	−1,130,000			3,394,219 By InterWest Partners X, L.P.	Filing · EDGAR

PMV Pharmaceuticals 10% owner · filings 2020 to 2021 · bought $2M

Date	Transaction	Shares	Price	Value	Held after	Source
Jul 13, 2021	Other acquisition or disposition (see the filing)	−500,000			4,469,911 direct	Filing · EDGAR
Jul 13, 2021	Other acquisition or disposition (see the filing)	+97,632			97,632 By: InterWest Management Partners X, LLC	Filing · EDGAR
Jul 13, 2021	Other acquisition or disposition (see the filing)	−97,632			0 By: InterWest Management Partners X, LLC	Filing · EDGAR
Jul 13, 2021	Other acquisition or disposition (see the filing)	+3,642			4,201 By: Khaled A. Nasr	Filing · EDGAR
Jul 13, 2021	Other acquisition or disposition (see the filing)	+2,441			2,816 By: Keval Desai	Filing · EDGAR
Jul 13, 2021	Other acquisition or disposition (see the filing)	+22,148			25,552 By Gilbert H. Kliman	Filing · EDGAR
May 10, 2021	Other acquisition or disposition (see the filing)	−500,000			4,969,911 direct	Filing · EDGAR
May 10, 2021	Other acquisition or disposition (see the filing)	+5,000			5,000 By: InterWest Management Partners X, LLC	Filing · EDGAR
May 10, 2021	Other acquisition or disposition (see the filing)	−5,000			0 By: InterWest Management Partners X, LLC	Filing · EDGAR
May 10, 2021	Other acquisition or disposition (see the filing)	+186			559 By: Khaled A. Nasr	Filing · EDGAR
May 10, 2021	Other acquisition or disposition (see the filing)	+125			375 By: Keval Desai	Filing · EDGAR
May 10, 2021	Other acquisition or disposition (see the filing)	+1,135			3,404 By Gilbert H. Kliman	Filing · EDGAR
Mar 24, 2021	Other acquisition or disposition (see the filing)	−1,000,000			5,469,911 direct	Filing · EDGAR
Mar 24, 2021	Other acquisition or disposition (see the filing)	+10,000			10,000 By: InterWest Management Partners X, LLC	Filing · EDGAR
Mar 24, 2021	Other acquisition or disposition (see the filing)	−10,000			0 By: InterWest Management Partners X, LLC	Filing · EDGAR
Mar 24, 2021	Other acquisition or disposition (see the filing)	+373			373 By: Khaled A. Nasr	Filing · EDGAR
Mar 24, 2021	Other acquisition or disposition (see the filing)	+250			250 By: Keval Desai	Filing · EDGAR
Mar 24, 2021	Other acquisition or disposition (see the filing)	+2,269			2,269 By Gilbert H. Kliman	Filing · EDGAR
Sep 29, 2020	Derivative converted	+1,620,101			1,675,656 direct	Filing · EDGAR
Sep 29, 2020	Derivative converted	+3,488,398			5,164,054 direct	Filing · EDGAR
Sep 29, 2020	Derivative converted	+1,040,654			6,204,708 direct	Filing · EDGAR
Sep 29, 2020	Derivative converted	+265,203			6,469,911 direct	Filing · EDGAR
Sep 29, 2020	Derivative converted Series Seed Preferred Stock	−1,620,101			0 direct	Filing · EDGAR
Sep 29, 2020	Derivative converted Series A Preferred Stock	−3,488,398			0 direct	Filing · EDGAR
Sep 29, 2020	Derivative converted Series B Preferred Stock	−1,040,654			0 direct	Filing · EDGAR
Sep 29, 2020	Derivative converted Series C Preferred Stock	−265,203			0 direct	Filing · EDGAR
Sep 25, 2020	Open-market or private purchase	+55,555	$18.00	$1M	55,555 direct	Filing · EDGAR
Sep 25, 2020	Open-market or private purchase	+55,000	$18.00	$990K	55,000 direct	Filing · EDGAR

Avedro 10% owner · filings 2019 to 2019 · bought $350K

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 21, 2019	Tendered in a change of control	−2,742,239	$63.07	$173M	0 direct	Filing · EDGAR
Nov 21, 2019	Tendered in a change of control	−3,005	$63.07	$190K	0 See Footnote	Filing · EDGAR
Jun 14, 2019	Grant or award from the company Restricted Stock Units	+3,005			3,005 direct	Filing · EDGAR
Feb 19, 2019	Derivative converted	+2,247,190			2,348,802 See Footnote	Filing · EDGAR
Feb 19, 2019	Derivative converted	+222,119			2,570,921 See Footnote	Filing · EDGAR
Feb 19, 2019	Derivative converted	+171,318			2,742,239 See Footnote	Filing · EDGAR
Feb 19, 2019	Open-market or private purchase	+25,000	$14.00	$350K	25,000 direct	Filing · EDGAR
Feb 19, 2019	Derivative converted Series AA Convertible Preferred Stock	−2,247,190			0 See Footnote	Filing · EDGAR
Feb 19, 2019	Derivative converted Series BB Convertible Preferred Stock	−222,119			0 See Footnote	Filing · EDGAR
Feb 19, 2019	Derivative converted Series CC Convertible Preferred Stock	−171,318			0 See Footnote	Filing · EDGAR
Feb 19, 2019	Grant or award from the company Stock Option (right to buy)	+8,314			8,314 direct	Filing · EDGAR

Venus Concept Director, 10% owner · filings 2017 to 2019 · bought $3M

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 7, 2019	Derivative converted	+301,605	$0.47	$141K	658,657 See footnote	Filing · EDGAR
Nov 7, 2019	Derivative converted Unsecured Subordinated Convertible Promissory Note				0 See footnote	Filing · EDGAR
Aug 20, 2019	Open-market or private purchase Unsecured Subordinated Convertible Promissory Note		$2,000,000.00		4,288,164 See Footnote	Filing · EDGAR
Aug 9, 2018	Open-market or private purchase	+2,000,000	$1.50	$3M	5,355,786 See Footnote	Filing · EDGAR
Jun 13, 2018	Grant or award from the company Stock Option (Right to Buy)	+13,708			13,708 direct	Filing · EDGAR
Oct 16, 2017	Derivative converted	+1,538,461			1,538,461 See Footnote	Filing · EDGAR
Oct 16, 2017	Derivative converted	+1,647,297			3,185,758 See Footnote	Filing · EDGAR
Oct 16, 2017	Derivative converted	+170,028	$7.00	$1.2M	3,355,786 See Footnote	Filing · EDGAR
Oct 16, 2017	Derivative converted Series B Preferred Stock	−1,538,461			0 See Footnote	Filing · EDGAR
Oct 16, 2017	Derivative converted Series C Preferred Stock	−1,647,297			0 See Footnote	Filing · EDGAR
Oct 16, 2017	Derivative converted Convertible Promissory Note				0 See Footnote	Filing · EDGAR
Oct 11, 2017	Other acquisition or disposition (see the filing) Convertible Promissory Note		$1,183,713.69			Filing · EDGAR

Obalon Therapeutics 10% owner · filings 2016 to 2019 · bought $2.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 6, 2019	Open-market or private purchase	+25,000	$4.00	$100K	380,224 direct	Filing · EDGAR
Aug 6, 2019	Open-market or private purchase Warrants (Right to buy)	+18,750			18,750 direct	Filing · EDGAR
Aug 23, 2018	Open-market or private purchase	+1,098,901	$1.82	$2M	3,552,239 direct	Filing · EDGAR
Oct 12, 2016	Derivative converted	+1,615,041			1,615,041 direct	Filing · EDGAR
Oct 12, 2016	Derivative converted	+464,494			2,079,535 direct	Filing · EDGAR
Oct 12, 2016	Derivative converted	+373,803			2,453,338 direct	Filing · EDGAR
Oct 12, 2016	Derivative converted Series C Preferred Stock	−1,615,041			0 direct	Filing · EDGAR
Oct 12, 2016	Derivative converted Series D Preferred Stock	−464,494			0 direct	Filing · EDGAR
Oct 12, 2016	Derivative converted Series E Preferred Stock	−373,803			0 direct	Filing · EDGAR

Eiger BioPharmaceuticals 10% owner · filings 2016 to 2018 · sold $2.9M

Date	Transaction	Shares	Price	Value	Held after	Source
Oct 18, 2018	Open-market or private sale	−210,800	$12.07	$2.5M	1,388,792 direct	Filing · EDGAR
Oct 18, 2018	Open-market or private sale	−26,465	$12.00	$318K	1,362,327 direct	Filing · EDGAR

Invuity 10% owner · filings 2015 to 2015

Date	Transaction	Shares	Held after	Source
Jun 18, 2015	Derivative converted	+1,080,272	1,080,272 direct	Filing · EDGAR
Jun 18, 2015	Derivative converted Series C Preferred Stock	−712,291	0 direct	Filing · EDGAR
Jun 18, 2015	Derivative converted Series D Preferred Stock	−262,310	0 direct	Filing · EDGAR
Jun 18, 2015	Derivative converted Series E Preferred Stock	−56,368	0 direct	Filing · EDGAR

Carbylan Therapeutics 10% owner · filings 2015 to 2015 · bought $4.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 14, 2015	Derivative converted	+831,531			831,531 See Footnote	Filing · EDGAR
Apr 14, 2015	Derivative converted	+2,145,351			2,976,882 See Footnote	Filing · EDGAR
Apr 14, 2015	Derivative converted	+466,357	$5.00	$2.3M	3,443,239 See Footnote	Filing · EDGAR
Apr 14, 2015	Derivative converted	+365,957	$5.00	$1.8M	3,809,196 See Footnote	Filing · EDGAR
Apr 14, 2015	Open-market or private purchase	+810,000	$5.00	$4.1M	4,619,196 See Footnote	Filing · EDGAR
Apr 14, 2015	Derivative converted Series A Convertible Preferred Stock	−831,531			0 See Footnote	Filing · EDGAR
Apr 14, 2015	Derivative converted Series B Convertible Preferred Stock	−2,145,351			0 See Footnote	Filing · EDGAR
Apr 14, 2015	Derivative converted Convertible Promissory Note	−466,357			0 See Footnote	Filing · EDGAR
Apr 14, 2015	Derivative converted Convertible Promissory Note	−365,957			0 See Footnote	Filing · EDGAR

Marketo 10% owner · filings 2013 to 2014 · sold $77.8M

Date	Transaction	Shares	Price	Value	Held after	Source
May 30, 2014	Open-market or private sale	−19,373	$23.20	$449K	0 By Gilbert H. Kliman	Filing · EDGAR
May 30, 2014	Open-market or private sale	−1,034	$24.16	$25K	49,266 By Philip T. Gianos	Filing · EDGAR
May 30, 2014	Open-market or private sale	−16,613	$23.06	$383K	0 By Khaled A. Nasr	Filing · EDGAR
May 29, 2014	Open-market or private sale	−21,821	$24.58	$536K	19,373 By Gilbert H. Kliman	Filing · EDGAR
May 29, 2014	Open-market or private sale	−11,298	$24.59	$278K	0 By Bruce A. Cleveland	Filing · EDGAR
May 29, 2014	Open-market or private sale	−9,118	$24.56	$224K	0 By Nina S. Kjellson	Filing · EDGAR
May 29, 2014	Open-market or private sale	−23,133	$24.57	$568K	50,300 By Philip T. Gianos	Filing · EDGAR
May 29, 2014	Open-market or private sale	−22,090	$24.57	$543K	16,613 By Khaled A. Nasr	Filing · EDGAR
May 28, 2014	Other acquisition or disposition (see the filing)	−974,000			3,715,756 direct	Filing · EDGAR
May 28, 2014	Other acquisition or disposition (see the filing)	+194,800			194,800 By InterWest Management Partners IX, LLC	Filing · EDGAR
May 28, 2014	Other acquisition or disposition (see the filing)	−194,800			0 By InterWest Management Partners IX, LLC	Filing · EDGAR
May 28, 2014	Other acquisition or disposition (see the filing)	+26,393			73,433 By Philip T. Gianos	Filing · EDGAR
May 28, 2014	Other acquisition or disposition (see the filing)	+34,130			120,819 By Arnold L. Oronsky	Filing · EDGAR
May 28, 2014	Other acquisition or disposition (see the filing)	+25,597			41,194 By Gilbert H. Kliman	Filing · EDGAR
May 28, 2014	Other acquisition or disposition (see the filing)	+8,532			30,204 By W. Stephen Holmes	Filing · EDGAR
May 28, 2014	Other acquisition or disposition (see the filing)	+9,118			9,118 By Nina S. Kjellson	Filing · EDGAR
May 28, 2014	Other acquisition or disposition (see the filing)	+11,298			11,298 By Bruce A. Cleveland	Filing · EDGAR
May 28, 2014	Other acquisition or disposition (see the filing)	+10,933			38,703 By Khaled A. Nasr	Filing · EDGAR
May 21, 2014	Open-market or private sale	−5,000	$24.00	$120K	15,597 By Gilbert H. Kliman	Filing · EDGAR
May 20, 2014	Open-market or private sale	−5,000	$24.02	$120K	20,597 By Gilbert H. Kliman	Filing · EDGAR
May 16, 2014	Open-market or private sale	−15,000	$22.96	$344K	25,597 By Gilbert H. Kliman	Filing · EDGAR
May 14, 2014	Open-market or private sale	−8,463	$24.34	$206K	0 By Nina S. Kjellson	Filing · EDGAR
May 13, 2014	Open-market or private sale	−11,298	$24.25	$274K	0 By Bruce A. Cleveland	Filing · EDGAR
May 13, 2014	Open-market or private sale	−14,695	$24.26	$356K	8,463 By Nina S. Kjellson	Filing · EDGAR
May 12, 2014	Other acquisition or disposition (see the filing)	−974,000			4,689,756 direct	Filing · EDGAR
May 12, 2014	Other acquisition or disposition (see the filing)	+194,800			194,800 By InterWest Management Partners IX, LLC	Filing · EDGAR
May 12, 2014	Other acquisition or disposition (see the filing)	−194,800			0 By InterWest Management Partners IX, LLC	Filing · EDGAR
May 12, 2014	Other acquisition or disposition (see the filing)	+26,393			47,040 By Philip T. Gianos	Filing · EDGAR
May 12, 2014	Other acquisition or disposition (see the filing)	+34,130			86,689 By Arnold L. Oronsky	Filing · EDGAR
May 12, 2014	Other acquisition or disposition (see the filing)	+25,597			40,597 By Gilbert H. Kliman	Filing · EDGAR
May 12, 2014	Other acquisition or disposition (see the filing)	+8,532			21,672 By W. Stephen Holmes	Filing · EDGAR
May 12, 2014	Other acquisition or disposition (see the filing)	+9,118			23,158 By Nina S. Kjellson	Filing · EDGAR
May 12, 2014	Other acquisition or disposition (see the filing)	+11,298			11,298 By Bruce A. Cleveland	Filing · EDGAR
May 12, 2014	Other acquisition or disposition (see the filing)	+10,933			27,770 By Khaled A. Nasr	Filing · EDGAR
Feb 28, 2014	Open-market or private sale	−5,000	$41.56	$208K	15,000 By Gilbert H. Kliman	Filing · EDGAR
Feb 27, 2014	Open-market or private sale	−19,420	$42.06	$817K	20,000 By Gilbert H. Kliman	Filing · EDGAR
Feb 26, 2014	Open-market or private sale	−20,000	$40.62	$812K	20,647 By Philip T. Gianos	Filing · EDGAR
Feb 26, 2014	Open-market or private sale	−13,050	$40.03	$522K	0 By Bruce A. Cleveland	Filing · EDGAR
Feb 25, 2014	Other acquisition or disposition (see the filing)	−1,500,000			5,663,756 direct	Filing · EDGAR
Feb 25, 2014	Other acquisition or disposition (see the filing)	+225,000			225,000 by InterWest Management Partners IX, LLC	Filing · EDGAR
Feb 25, 2014	Other acquisition or disposition (see the filing)	−225,000			0 by InterWest Management Partners IX, LLC	Filing · EDGAR
Feb 25, 2014	Other acquisition or disposition (see the filing)	+30,485			40,647 by Philip T. Gianos	Filing · EDGAR
Feb 25, 2014	Other acquisition or disposition (see the filing)	+39,420			52,559 by Arnold L. Oronsky	Filing · EDGAR
Feb 25, 2014	Other acquisition or disposition (see the filing)	+29,565			39,420 by Gilbert H. Kliman	Filing · EDGAR
Feb 25, 2014	Other acquisition or disposition (see the filing)	+9,855			13,140 by W. Stephen Holmes	Filing · EDGAR
Feb 25, 2014	Other acquisition or disposition (see the filing)	+10,530			14,040 by Nina S. Kjellson	Filing · EDGAR
Feb 25, 2014	Other acquisition or disposition (see the filing)	+13,050			13,050 by Bruce A. Cleveland	Filing · EDGAR
Feb 25, 2014	Other acquisition or disposition (see the filing)	+12,628			16,837 By Khaled A. Nasr	Filing · EDGAR
Feb 13, 2014	Open-market or private sale	−4,350	$40.70	$177K	0 by Bruce A. Cleveland	Filing · EDGAR
Feb 12, 2014	Other acquisition or disposition (see the filing)	−500,000			7,163,756 direct	Filing · EDGAR
Feb 12, 2014	Other acquisition or disposition (see the filing)	+75,000			75,000 by InterWest Management Partners IX, LLC	Filing · EDGAR
Feb 12, 2014	Other acquisition or disposition (see the filing)	−75,000			0 by InterWest Management Partners IX, LLC	Filing · EDGAR
Feb 12, 2014	Other acquisition or disposition (see the filing)	+10,162			10,162 by Philip T. Gianos	Filing · EDGAR
Feb 12, 2014	Other acquisition or disposition (see the filing)	+13,139			13,139 by Arnold L. Oronsky	Filing · EDGAR
Feb 12, 2014	Other acquisition or disposition (see the filing)	+9,855			9,855 by Gilbert H. Kliman	Filing · EDGAR
Feb 12, 2014	Other acquisition or disposition (see the filing)	+3,285			3,285 by W. Stephen Holmes	Filing · EDGAR
Feb 12, 2014	Other acquisition or disposition (see the filing)	+3,510			3,510 by Nina S. Kjellson	Filing · EDGAR
Feb 12, 2014	Other acquisition or disposition (see the filing)	+4,350			4,350 by Bruce A. Cleveland	Filing · EDGAR
Feb 12, 2014	Other acquisition or disposition (see the filing)	+4,209			4,209 By Khaled A. Nasr	Filing · EDGAR
Sep 18, 2013	Open-market or private sale	−2,083,435	$33.99	$70.8M	7,663,756 See footnote	Filing · EDGAR

6 earlier transactions are in the filing list below.

Applied Genetic Technologies 10% owner · filings 2014 to 2014 · bought $905K

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 1, 2014	Derivative converted	+1,376,480			1,376,480 See Footnote	Filing · EDGAR
Apr 1, 2014	Open-market or private purchase	+75,376	$12.00	$905K	1,452,216 See Footnote	Filing · EDGAR
Apr 1, 2014	Derivative converted Series A-1 Convertible Preferred Stock	−11,479,011			0 See Footnote	Filing · EDGAR
Apr 1, 2014	Derivative converted Series B-1 Convertible Preferred Stock	−6,409,436			0 See Footnote	Filing · EDGAR
Apr 1, 2014	Derivative converted Series B-2 Convertible Preferred Stock	−11,893,926			0 See Footnote	Filing · EDGAR
Apr 1, 2014	Derivative converted Series B-3 Convertible Preferred Stock	−5,699,111			0 See Footnote	Filing · EDGAR
Apr 1, 2014	Derivative converted Series B-1 Warrant	−416,361			0 See Footnote	Filing · EDGAR
Apr 1, 2014	Derivative converted Common Stock Warrant	+11,895			11,895 See Footnote	Filing · EDGAR

Macrogenics 10% owner · filings 2013 to 2013

Date	Transaction	Shares	Held after	Source
Oct 16, 2013	Derivative converted	+962,819	962,819 See Footnote	Filing · EDGAR
Oct 16, 2013	Derivative converted	+615,284	1,578,103 See Footnote	Filing · EDGAR
Oct 16, 2013	Derivative converted	+295,494	1,873,597 See Footnote	Filing · EDGAR
Oct 16, 2013	Derivative converted	+32,671	1,906,268 See Footnote	Filing · EDGAR
Oct 16, 2013	Derivative converted	+2,448	1,908,716 See Footnote	Filing · EDGAR
Oct 16, 2013	Derivative converted Series A-1 Convertible Preferred Stock	−12,001,000	0 See Footnote	Filing · EDGAR
Oct 16, 2013	Derivative converted Series B Convertible Preferred Stock	−10,131,856	0 See Footnote	Filing · EDGAR
Oct 16, 2013	Derivative converted Series C Convertible Preferred Stock	−5,547,611	0 See Footnote	Filing · EDGAR
Oct 16, 2013	Derivative converted Series D-2 Convertible Preferred Stock	−613,402	0 See Footnote	Filing · EDGAR
Oct 16, 2013	In-the-money option exercised Series D-2 Convertible Preferred Stock Warrant to buy	−46,005	0 See Footnote	Filing · EDGAR
Oct 16, 2013	Derivative converted Series D-2 Convertible Preferred Stock	−2,448	0 See Footnote	Filing · EDGAR

TESARO Other · filings 2012 to 2013 · bought $6M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 5, 2013	Other acquisition or disposition (see the filing)	−600,000			2,471,701 direct	Filing · EDGAR
Jul 3, 2012	Derivative converted	+2,627,257			2,627,257 direct	Filing · EDGAR
Jul 3, 2012	Open-market or private purchase	+444,444	$13.50	$6M	3,071,701 direct	Filing · EDGAR
Jul 3, 2012	Derivative converted Series B Preferred Stock	−9,195,402			0 direct	Filing · EDGAR

Transcept Pharmaceuticals 10% owner · filings 2011 to 2011 · bought $1.6M

Date	Transaction	Shares	Price	Value	Held after	Source
Sep 21, 2011	Open-market or private purchase	+217,228	$7.24	$1.6M	1,983,884 direct	Filing · EDGAR

Epocrates Director, Other · filings 2011 to 2011 · sold $6.8M

Date	Transaction	Shares	Price	Value	Held after	Source
Feb 7, 2011	Derivative converted	+1,315,803			1,315,803 See Footnote	Filing · EDGAR
Feb 7, 2011	Derivative converted	+711,602			2,027,405 See Footnote	Filing · EDGAR
Feb 7, 2011	Derivative converted	+265,120			2,292,525 See Footnote	Filing · EDGAR
Feb 7, 2011	Open-market or private sale	−407,401	$16.00	$6.5M	1,885,124 See Footnote	Filing · EDGAR
Feb 7, 2011	Derivative converted	+59,696			59,696 See Footnote	Filing · EDGAR
Feb 7, 2011	Derivative converted	+34,005			93,701 See Footnote	Filing · EDGAR
Feb 7, 2011	Derivative converted	+12,208			105,909 See Footnote	Filing · EDGAR
Feb 7, 2011	Open-market or private sale	−18,822	$16.00	$301K	87,087 See Footnote	Filing · EDGAR
Feb 7, 2011	Derivative converted Series A Convertible Preferred Stock	−1,674,050			0 See Footnote	Filing · EDGAR
Feb 7, 2011	Derivative converted Series A Convertible Preferred Stock	−75,950			0 See Footnote	Filing · EDGAR
Feb 7, 2011	Derivative converted Series B Convertible Preferred Stock	−783,587			0 See Footnote	Filing · EDGAR
Feb 7, 2011	Derivative converted Series B Convertible Preferred Stock	−37,445			0 See Footnote	Filing · EDGAR
Feb 7, 2011	Derivative converted Series C Convertible Preferred Stock	−337,304			0 See Footnote	Filing · EDGAR
Feb 7, 2011	Derivative converted Series C Convertible Preferred Stock	−15,533			0 See Footnote	Filing · EDGAR

Trius Therapeutics Other · filings 2010 to 2010 · bought $6.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Aug 6, 2010	Derivative converted	+1,576,814			1,576,814 direct	Filing · EDGAR
Aug 6, 2010	Derivative converted	+744,496	$4.38	$3.3M	2,321,310 direct	Filing · EDGAR
Aug 6, 2010	Open-market or private purchase	+1,227,333	$5.00	$6.1M	3,548,643 direct	Filing · EDGAR
Aug 6, 2010	Derivative converted Series A-2 Convertible Preferred Stock	−9,090,910			0 direct	Filing · EDGAR
Aug 6, 2010	Derivative converted Series B Convertible Preferred Stock	−4,469,697			0 direct	Filing · EDGAR

Metabasis Therapeutics 10% owner · filings 2004 to 2008 · bought $5.7M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 16, 2008	Open-market or private purchase	+945,577	$2.34	$2.2M	3,456,030 direct	Filing · EDGAR
Apr 16, 2008	Open-market or private purchase	+45,239	$2.34	$106K	165,459 By InterWest Investors VII, L.P.	Filing · EDGAR
Apr 16, 2008	In-the-money option exercised	+118,759	$2.34	$278K	3,574,789 direct	Filing · EDGAR
Apr 16, 2008	In-the-money option exercised	+142,493	$2.34	$333K	3,717,282 direct	Filing · EDGAR
Apr 16, 2008	In-the-money option exercised	+5,687	$2.34	$13K	171,146 By InterWest Investors VII, L.P.	Filing · EDGAR
Apr 16, 2008	In-the-money option exercised	+6,824	$2.34	$16K	177,970 By InterWest Investors VII, L.P.	Filing · EDGAR
Apr 16, 2008	Long derivative expired or cancelled Common Stock Warrant (Right to Buy)	−118,759			0 direct	Filing · EDGAR
Apr 16, 2008	Long derivative expired or cancelled Common Stock Warrant (Right to Buy)	−142,493			0 direct	Filing · EDGAR
Apr 16, 2008	Long derivative expired or cancelled Common Stock Warrant (Right to Buy)	−5,687			0 By InterWest Investors VII, L.P.	Filing · EDGAR
Apr 16, 2008	Long derivative expired or cancelled Common Stock Warrant (Right to Buy)	−6,824			0 By InterWest Investors VII, L.P.	Filing · EDGAR
Apr 16, 2008	Open-market or private purchase Common Stock Warrant (Right to Buy)	+118,759			118,759 direct	Filing · EDGAR
Apr 16, 2008	Open-market or private purchase Common Stock Warrant (Right to Buy)	+142,493			142,493 direct	Filing · EDGAR
Apr 16, 2008	Open-market or private purchase Common Stock Warrant (Right to Buy)	+5,687			5,687 By InterWest Investors VII, L.P.	Filing · EDGAR
Apr 16, 2008	Open-market or private purchase Common Stock Warrant (Right to Buy)	+6,824			6,824 By InterWest Investors VII, L.P.	Filing · EDGAR
Apr 16, 2008	In-the-money option exercised Common Stock Warrant (Right to Buy)	−118,759			0 direct	Filing · EDGAR
Apr 16, 2008	In-the-money option exercised Common Stock Warrant (Right to Buy)	−142,493			0 direct	Filing · EDGAR
Apr 16, 2008	In-the-money option exercised Common Stock Warrant (Right to Buy)	−5,687			0 By InterWest Investors VII, L.P.	Filing · EDGAR
Apr 16, 2008	In-the-money option exercised Common Stock Warrant (Right to Buy)	−6,824			0 By InterWest Investors VII, L.P.	Filing · EDGAR
Apr 16, 2008	Open-market or private purchase Common Stock Warrant (Right to Buy)	+312,173			312,173 direct	Filing · EDGAR
Apr 16, 2008	Open-market or private purchase Common Stock Warrant (Right to Buy)	+14,937			14,937 By InterWest Investors VII, L.P.	Filing · EDGAR
Sep 30, 2005	Open-market or private purchase	+407,124	$5.86	$2.4M	2,510,453 direct	Filing · EDGAR
Sep 30, 2005	Open-market or private purchase	+19,497	$5.86	$114K	120,220 By: InterWest Investors VII, LP	Filing · EDGAR
Sep 30, 2005	Open-market or private purchase Common Stock Warrant (right to buy)	+142,493			142,493 direct	Filing · EDGAR
Sep 30, 2005	Open-market or private purchase Common Stock Warrant (right to buy)	+6,824			6,824 By: InterWest Investors VII, LP	Filing · EDGAR
Jun 21, 2004	Derivative converted	+1,979,270			1,979,270 direct	Filing · EDGAR
Jun 21, 2004	Derivative converted	+94,782			94,782 See footnote	Filing · EDGAR
Jun 21, 2004	Open-market or private purchase	+124,059	$7.00	$868K	124,059 direct	Filing · EDGAR
Jun 21, 2004	Open-market or private purchase	+5,941	$7.00	$42K	5,941 See footnote	Filing · EDGAR
Jun 21, 2004	Derivative converted Series C Convertible Preferred Stock	−782,411			0 direct	Filing · EDGAR
Jun 21, 2004	Derivative converted Series C Convertible Preferred Stock	−37,468			0 See footnote	Filing · EDGAR
Jun 21, 2004	Derivative converted Series D Convertible Preferred Stock	−539,815			0 direct	Filing · EDGAR
Jun 21, 2004	Derivative converted Series D Convertible Preferred Stock	−25,850			0 See footnote	Filing · EDGAR
Jun 21, 2004	Derivative converted Series E Convertible Preferred Stock	−657,044			0 direct	Filing · EDGAR
Jun 21, 2004	Derivative converted Series E Convertible Preferred Stock	−31,464			0 See footnote	Filing · EDGAR

Anesiva 10% owner · filings 2005 to 2007 · bought $8.1M

Date	Transaction	Shares	Price	Value	Held after	Source
Dec 18, 2007	Open-market or private purchase	+1,905,581	$4.05	$7.7M	4,627,266 direct	Filing · EDGAR
Dec 18, 2007	Open-market or private purchase	+15,210	$4.05	$62K	37,079 By InterWest Investors VIII, L.P.	Filing · EDGAR
Dec 18, 2007	Open-market or private purchase	+54,518	$4.05	$221K	132,388 By InterWest Investors Q VIII, L.P.	Filing · EDGAR
Mar 17, 2006	Open-market or private purchase	+5,000	$8.97	$45K	12,283 direct	Filing · EDGAR
Mar 17, 2006	Other acquisition or disposition (see the filing)	+0			2,721,685 by InterWest Partners VIII, LP	Filing · EDGAR
Mar 17, 2006	Other acquisition or disposition (see the filing)	+0			77,870 by InterWest Investors Q VIII, LP	Filing · EDGAR
Mar 17, 2006	Other acquisition or disposition (see the filing)	+0			21,869 by InterWest Investors VIII, LP	Filing · EDGAR
Mar 9, 2006	Open-market or private purchase	+1,000	$9.95	$10K	7,283 direct	Filing · EDGAR

EnteroMedics 10% owner · filings 2007 to 2007 · bought $1.5M

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 20, 2007	Derivative converted	+1,359,261			1,546,761 direct	Filing · EDGAR
Nov 20, 2007	Derivative converted Series C Preferred Stock	−1,359,261			0 direct	Filing · EDGAR
Nov 15, 2007	Open-market or private purchase	+187,500	$8.00	$1.5M	187,500 direct	Filing · EDGAR

Intralase Director · filings 2004 to 2007 · sold $1.3M

Date	Transaction	Shares	Price	Value	Held after	Source
Apr 2, 2007	Returned to the company Employee Stock Option (right to buy)	−12,000	$6.11	$73K	0 direct	Filing · EDGAR
Apr 2, 2007	Returned to the company Employee Stock Option (right to buy)	−274	$5.07	$1K	0 direct	Filing · EDGAR
Apr 2, 2007	Returned to the company Employee Stock Option (right to buy)	−248	$2.64	$655	0 direct	Filing · EDGAR
Apr 2, 2007	Returned to the company Employee Stock Option (right to buy)	−294	$6.77	$2K	0 direct	Filing · EDGAR
Apr 2, 2007	Returned to the company Employee Stock Option (right to buy)	−305	$6.71	$2K	0 direct	Filing · EDGAR
Apr 2, 2007	Returned to the company Employee Stock Option (right to buy)	−319	$8.09	$3K	0 direct	Filing · EDGAR
Apr 2, 2007	Returned to the company Employee Stock Option (right to buy)	−335	$7.86	$3K	0 direct	Filing · EDGAR
Apr 2, 2007	Returned to the company Employee Stock Option (right to buy)	−12,000	$5.61	$67K	0 direct	Filing · EDGAR
Apr 2, 2007	Returned to the company Employee Stock Option (right to buy)	−374	$10.15	$4K	0 direct	Filing · EDGAR
Apr 2, 2007	Returned to the company Employee Stock Option (right to buy)	−319	$8.09	$3K	0 direct	Filing · EDGAR
Oct 2, 2006	Grant or award from the company Non-Qualified Stock Option (right to buy)	+294			294 direct	Filing · EDGAR
Jul 3, 2006	Grant or award from the company Non-Qualified Stock Option (right to buy)	+335			335 direct	Filing · EDGAR
May 24, 2006	Grant or award from the company Non-Qualified Stock Option (right to buy)	+12,000			12,000 direct	Filing · EDGAR
May 19, 2006	Open-market or private sale	−2,054	$19.50	$40K	0 direct	Filing · EDGAR
May 1, 2006	Open-market or private sale	−46,746	$20.47	$957K	0 By InterWest Investors Q VIII, LP	Filing · EDGAR
May 1, 2006	Open-market or private sale	−13,927	$20.47	$285K	0 By InterWest Investors VIII, LP	Filing · EDGAR
Apr 28, 2006	Other acquisition or disposition (see the filing)	−1,633,014			0 by InterWest Partners VIII, LP	Filing · EDGAR
Apr 28, 2006	Other acquisition or disposition (see the filing)	+16,330			16,330 By InterWest Management Partners VIII, LLC	Filing · EDGAR
Apr 28, 2006	Other acquisition or disposition (see the filing)	−16,330			0 By InterWest Management Partners VIII, LLC	Filing · EDGAR
Apr 28, 2006	Other acquisition or disposition (see the filing)	+2,054			2,054 direct	Filing · EDGAR
Apr 3, 2006	Grant or award from the company Non-Qualified Stock Option (right to buy)	+248			248 direct	Filing · EDGAR
Jan 5, 2006	Grant or award from the company Non-Qualified Stock Option (right to buy)	+305			305 direct	Filing · EDGAR
Oct 3, 2005	Grant or award from the company Non-Qualified Stock Option (right to buy)	+374			374 direct	Filing · EDGAR
Jul 22, 2005	Grant or award from the company Non-Qualified Stock Option (right to buy)	+12,000			12,000 direct	Filing · EDGAR
Jul 1, 2005	Grant or award from the company Non-Qualified Stock Option (right to buy)	+274			274 direct	Filing · EDGAR
Jun 16, 2005	Open-market or private sale	−2,408	$19.22	$46K	0 direct	Filing · EDGAR
Jun 7, 2005	Other acquisition or disposition (see the filing)	−1,633,015			1,633,014 by InterWest Partners VIII, LP	Filing · EDGAR
Jun 7, 2005	Other acquisition or disposition (see the filing)	−13,930			13,927 by InterWest Investors VIII, LP	Filing · EDGAR
Jun 7, 2005	Other acquisition or disposition (see the filing)	−46,745			46,746 by InterWest Investors Q VIII, LP	Filing · EDGAR
Jun 7, 2005	Other acquisition or disposition (see the filing)	+16,936			16,936 by InterWest Management Partners VIII, LLC	Filing · EDGAR
Jun 7, 2005	Other acquisition or disposition (see the filing)	−16,936			0 By InterWest Management Partners VIII, LLC	Filing · EDGAR
Jun 7, 2005	Other acquisition or disposition (see the filing)	+2,408			2,408 direct	Filing · EDGAR
Apr 1, 2005	Grant or award from the company Non-Qualified Stock Option (right to buy)	+319			319 direct	Filing · EDGAR
Apr 1, 2005	Grant or award from the company Non-Qualified Stock Option (right to buy)	+319			638 direct	Filing · EDGAR
Oct 13, 2004	Derivative converted	+1,996,823			1,996,823 By InterWest Partners VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted	+57,170			57,170 By InterWest Investors Q VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted	+17,400			17,400 By InterWest Investors VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted	+664,262			664,262 By InterWest Partners VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted	+19,004			19,004 By InterWest Investors Q VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted	+5,302			5,302 By InterWest Investors VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted	+604,944			604,944 By InterWest Partners VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted	+17,317			17,317 By InterWest Investors Q VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted	+5,155			5,155 By InterWest Investors VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted Series E Preferred Stock	−2,263,797			0 By InterWest Partners VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted Series E Preferred Stock	−64,814			0 By InterWest Investors Q VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted Series E Preferred Stock	−19,726			0 By InterWest Investors VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted Series F Preferred Stock	−920,632			0 By InterWest Partners VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted Series F Preferred Stock	−26,339			0 By InterWest Investors Q VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted Series F Preferred Stock	−7,348			0 By InterWest Investors VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted Series G Preferred Stock	−838,421			0 By InterWest Partners VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted Series G Preferred Stock	−24,000			0 By InterWest Investors Q VIII, L.P.	Filing · EDGAR
Oct 13, 2004	Derivative converted Series G Preferred Stock	−7,144			0 By InterWest Investors VIII, L.P.	Filing · EDGAR

Myogen 10% owner · filings 2005 to 2005

Date	Transaction	Shares	Held after	Source
Jun 28, 2005	Other acquisition or disposition (see the filing)	−278,700	835,969 direct	Filing · EDGAR
Jun 28, 2005	Other acquisition or disposition (see the filing)	+2,787	2,787 by InterWest Management Parnters VI, LLC	Filing · EDGAR
Jun 28, 2005	Other acquisition or disposition (see the filing)	−2,787	0 by InterWest ManagementPartners VI, LLC	Filing · EDGAR
Jun 28, 2005	Other acquisition or disposition (see the filing)	+758	758 by Harvey B. Cash	Filing · EDGAR
Jun 28, 2005	Other acquisition or disposition (see the filing)	+1,327	1,327 by Philip T. Gianos	Filing · EDGAR
Jun 28, 2005	Other acquisition or disposition (see the filing)	+330	330 by W. Scott Hedrick	Filing · EDGAR
Jun 28, 2005	Other acquisition or disposition (see the filing)	+291	291 by W. Stephen Holmes	Filing · EDGAR
Jun 28, 2005	Other acquisition or disposition (see the filing)	+771	10,771 by Gilbert H. Kliman	Filing · EDGAR
Jun 28, 2005	Other acquisition or disposition (see the filing)	+398	398 by Robert R. Momsen	Filing · EDGAR

All 154 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Nov 5, 2026	Form 4	GLAUKOS GKOS	Filing · EDGAR
Nov 4, 2026	Form 144	GLAUKOS GKOS	Filing · EDGAR
Aug 20, 2026	Form 4	GLAUKOS GKOS	Filing · EDGAR
Aug 19, 2026	Form 144	GLAUKOS GKOS	Filing · EDGAR
Jun 23, 2026	Form 4/A	GLAUKOS GKOS	Filing · EDGAR
Jun 1, 2026	Form 4	GLAUKOS GKOS	Filing · EDGAR
May 18, 2026	Form 4	GLAUKOS GKOS	Filing · EDGAR
May 14, 2026	Form 144	GLAUKOS GKOS	Filing · EDGAR
May 13, 2026	Form 4	GLAUKOS GKOS	Filing · EDGAR
May 11, 2026	Form 144	GLAUKOS GKOS	Filing · EDGAR
Jan 7, 2026	Form 4	GLAUKOS GKOS	Filing · EDGAR
Dec 11, 2025	Form 4	GLAUKOS GKOS	Filing · EDGAR
Dec 9, 2025	Form 144	GLAUKOS GKOS	Filing · EDGAR
Jun 2, 2025	Form 4	GLAUKOS GKOS	Filing · EDGAR
Dec 23, 2024	Form 4	GLAUKOS GKOS	Filing · EDGAR
Dec 20, 2024	Form 144	GLAUKOS GKOS	Filing · EDGAR
Dec 13, 2024	Form 4	GLAUKOS GKOS	Filing · EDGAR
Dec 11, 2024	Form 144	GLAUKOS GKOS	Filing · EDGAR
Sep 11, 2024	Form 4	GLAUKOS GKOS	Filing · EDGAR
Sep 9, 2024	Form 144	GLAUKOS GKOS	Filing · EDGAR
Jun 3, 2024	Form 4	GLAUKOS GKOS	Filing · EDGAR
May 30, 2024	Form 144	GLAUKOS GKOS	Filing · EDGAR
Mar 8, 2024	Form 4	GLAUKOS GKOS	Filing · EDGAR
Mar 7, 2024	Form 144	GLAUKOS GKOS	Filing · EDGAR
Feb 29, 2024	Form 4	GLAUKOS GKOS	Filing · EDGAR
Jan 4, 2024	Form 4	GLAUKOS GKOS	Filing · EDGAR
Dec 5, 2023	Form 4	Staar Surgical	Filing · EDGAR
Dec 4, 2023	Form 4	Staar Surgical	Filing · EDGAR
Oct 3, 2023	Form 4	Staar Surgical	Filing · EDGAR
Aug 8, 2023	Form 4	GLAUKOS GKOS	Filing · EDGAR
Aug 4, 2023	Form 144	GLAUKOS GKOS	Filing · EDGAR
Jun 16, 2023	Form 4	Staar Surgical	Filing · EDGAR
Jun 5, 2023	Form 4	GLAUKOS GKOS	Filing · EDGAR
Jan 4, 2023	Form 4	GLAUKOS GKOS	Filing · EDGAR
Aug 19, 2022	Form 4	GLAUKOS GKOS	Filing · EDGAR
Aug 8, 2022	Form 4	GLAUKOS GKOS	Filing · EDGAR
Aug 5, 2022	Form 4	Doximity	Filing · EDGAR
Jul 29, 2022	Form 4	Doximity	Filing · EDGAR
Jun 17, 2022	Form 4	Staar Surgical	Filing · EDGAR
Jun 6, 2022	Form 4	GLAUKOS GKOS	Filing · EDGAR
May 18, 2022	Form 4	GLAUKOS GKOS	Filing · EDGAR
Feb 25, 2022	Form 4	Doximity	Filing · EDGAR
Feb 9, 2022	Form 4	Braze	Filing · EDGAR
Dec 8, 2021	Form 4	Doximity	Filing · EDGAR
Dec 6, 2021	Form 4	Doximity	Filing · EDGAR
Nov 23, 2021	Form 4	Braze	Filing · EDGAR
Nov 16, 2021	Form 3	Braze	Filing · EDGAR
Nov 15, 2021	Form 4	Doximity	Filing · EDGAR
Sep 10, 2021	Form 4	GLAUKOS GKOS	Filing · EDGAR
Jul 14, 2021	Form 4	PMV Pharmaceuticals	Filing · EDGAR
Jun 28, 2021	Form 4	Doximity	Filing · EDGAR
Jun 25, 2021	Form 4	Staar Surgical	Filing · EDGAR
Jun 23, 2021	Form 3	Doximity	Filing · EDGAR
Jun 7, 2021	Form 4	GLAUKOS GKOS	Filing · EDGAR
May 12, 2021	Form 4	PMV Pharmaceuticals	Filing · EDGAR
Mar 25, 2021	Form 4	PMV Pharmaceuticals	Filing · EDGAR
Mar 5, 2021	Form 4	GLAUKOS GKOS	Filing · EDGAR
Jan 6, 2021	Form 4	GLAUKOS GKOS	Filing · EDGAR
Oct 2, 2020	Form 4/A	PMV Pharmaceuticals	Filing · EDGAR
Sep 29, 2020	Form 4	PMV Pharmaceuticals	Filing · EDGAR
Sep 24, 2020	Form 3	PMV Pharmaceuticals	Filing · EDGAR
Aug 4, 2020	Form 4	Staar Surgical	Filing · EDGAR
Jun 5, 2020	Form 4	GLAUKOS GKOS	Filing · EDGAR
Jun 3, 2020	Form 4	Staar Surgical	Filing · EDGAR
Jun 3, 2020	Form 3	Staar Surgical	Filing · EDGAR
May 12, 2020	Form 4	GLAUKOS GKOS	Filing · EDGAR
Mar 16, 2020	Form 3	GLAUKOS GKOS	Filing · EDGAR
Nov 25, 2019	Form 4	Avedro	Filing · EDGAR
Nov 12, 2019	Form 4	Venus Concept	Filing · EDGAR
Aug 22, 2019	Form 4	Venus Concept	Filing · EDGAR
Aug 8, 2019	Form 4	Obalon Therapeutics	Filing · EDGAR
Jun 18, 2019	Form 4	Avedro	Filing · EDGAR
Jun 10, 2019	Form 4	GLAUKOS GKOS	Filing · EDGAR
May 31, 2019	Form 4	GLAUKOS GKOS	Filing · EDGAR
Feb 19, 2019	Form 4	Avedro	Filing · EDGAR
Feb 13, 2019	Form 3	Avedro	Filing · EDGAR
Jan 16, 2019	Form 4	GLAUKOS GKOS	Filing · EDGAR
Oct 22, 2018	Form 4	Eiger BioPharmaceuticals	Filing · EDGAR
Aug 31, 2018	Form 4	GLAUKOS GKOS	Filing · EDGAR
Aug 27, 2018	Form 4	Obalon Therapeutics	Filing · EDGAR
Aug 13, 2018	Form 4	Venus Concept	Filing · EDGAR
Jun 15, 2018	Form 4	Venus Concept	Filing · EDGAR
Jun 1, 2018	Form 4	GLAUKOS GKOS	Filing · EDGAR
Dec 14, 2017	Form 4	GLAUKOS GKOS	Filing · EDGAR
Oct 17, 2017	Form 4	Venus Concept	Filing · EDGAR
Oct 13, 2017	Form 4	Venus Concept	Filing · EDGAR
Oct 11, 2017	Form 3	Venus Concept	Filing · EDGAR
Dec 8, 2016	Form 4	GLAUKOS GKOS	Filing · EDGAR
Oct 12, 2016	Form 4	Obalon Therapeutics	Filing · EDGAR
Oct 5, 2016	Form 3	Obalon Therapeutics	Filing · EDGAR
Aug 3, 2016	Form 4	GLAUKOS GKOS	Filing · EDGAR
Jun 3, 2016	Form 4	GLAUKOS GKOS	Filing · EDGAR
Mar 31, 2016	Form 3	Eiger BioPharmaceuticals	Filing · EDGAR
Jul 24, 2015	Form 4	GLAUKOS GKOS	Filing · EDGAR
Jun 30, 2015	Form 4	GLAUKOS GKOS	Filing · EDGAR
Jun 24, 2015	Form 3	GLAUKOS GKOS	Filing · EDGAR
Jun 22, 2015	Form 4	Invuity	Filing · EDGAR
Jun 11, 2015	Form 3	Invuity	Filing · EDGAR
Apr 14, 2015	Form 4	Carbylan Therapeutics	Filing · EDGAR
Apr 8, 2015	Form 3	Carbylan Therapeutics	Filing · EDGAR
Jun 2, 2014	Form 4	Marketo	Filing · EDGAR
May 30, 2014	Form 4	Marketo	Filing · EDGAR
May 22, 2014	Form 4	Marketo	Filing · EDGAR
May 20, 2014	Form 4	Marketo	Filing · EDGAR
May 15, 2014	Form 4	Marketo	Filing · EDGAR
May 14, 2014	Form 4	Marketo	Filing · EDGAR
Apr 1, 2014	Form 4	Applied Genetic Technologies	Filing · EDGAR
Mar 26, 2014	Form 3	Applied Genetic Technologies	Filing · EDGAR
Mar 3, 2014	Form 4	Marketo	Filing · EDGAR
Feb 28, 2014	Form 4	Marketo	Filing · EDGAR
Feb 27, 2014	Form 4	Marketo	Filing · EDGAR
Feb 18, 2014	Form 4	Marketo	Filing · EDGAR
Feb 14, 2014	Form 4	Marketo	Filing · EDGAR
Oct 18, 2013	Form 4	Macrogenics	Filing · EDGAR
Oct 9, 2013	Form 3	Macrogenics	Filing · EDGAR
Sep 18, 2013	Form 4	Marketo	Filing · EDGAR
Aug 7, 2013	Form 4	TESARO	Filing · EDGAR
May 22, 2013	Form 4	Marketo	Filing · EDGAR
May 16, 2013	Form 3	Marketo	Filing · EDGAR
Jul 5, 2012	Form 4	TESARO	Filing · EDGAR
Jun 27, 2012	Form 3	TESARO	Filing · EDGAR
Sep 23, 2011	Form 4	Transcept Pharmaceuticals	Filing · EDGAR
Sep 22, 2011	Form 3	Transcept Pharmaceuticals	Filing · EDGAR
Feb 7, 2011	Form 4	Epocrates	Filing · EDGAR
Feb 1, 2011	Form 3	Epocrates	Filing · EDGAR
Aug 10, 2010	Form 4	Trius Therapeutics	Filing · EDGAR
Aug 2, 2010	Form 3	Trius Therapeutics	Filing · EDGAR
Apr 18, 2008	Form 4	Metabasis Therapeutics	Filing · EDGAR
Dec 20, 2007	Form 4	Anesiva	Filing · EDGAR
Nov 21, 2007	Form 4	EnteroMedics	Filing · EDGAR
Nov 19, 2007	Form 4	EnteroMedics	Filing · EDGAR
Nov 14, 2007	Form 3	EnteroMedics	Filing · EDGAR
Apr 4, 2007	Form 4	Intralase	Filing · EDGAR
Oct 3, 2006	Form 4	Intralase	Filing · EDGAR
Jul 5, 2006	Form 4	Intralase	Filing · EDGAR
May 26, 2006	Form 4	Intralase	Filing · EDGAR
May 19, 2006	Form 4	Intralase	Filing · EDGAR
May 1, 2006	Form 4	Intralase	Filing · EDGAR
Apr 4, 2006	Form 4	Intralase	Filing · EDGAR
Mar 31, 2006	Form 3/A	Anesiva	Filing · EDGAR
Mar 20, 2006	Form 4	Anesiva	Filing · EDGAR
Jan 9, 2006	Form 4	Intralase	Filing · EDGAR
Dec 21, 2005	Form 3	Anesiva	Filing · EDGAR
Oct 4, 2005	Form 4	Intralase	Filing · EDGAR
Oct 4, 2005	Form 4	Metabasis Therapeutics	Filing · EDGAR
Jul 25, 2005	Form 4	Intralase	Filing · EDGAR
Jul 6, 2005	Form 4	Intralase	Filing · EDGAR
Jun 30, 2005	Form 4	Myogen	Filing · EDGAR
Jun 17, 2005	Form 4	Intralase	Filing · EDGAR
Jun 9, 2005	Form 4	Intralase	Filing · EDGAR
Apr 5, 2005	Form 4	Intralase	Filing · EDGAR
Oct 13, 2004	Form 4	Intralase	Filing · EDGAR
Oct 6, 2004	Form 3	Intralase	Filing · EDGAR
Jun 23, 2004	Form 4	Metabasis Therapeutics	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.